0001127602-20-009708.txt : 20200305
0001127602-20-009708.hdr.sgml : 20200305
20200305194402
ACCESSION NUMBER: 0001127602-20-009708
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200303
FILED AS OF DATE: 20200305
DATE AS OF CHANGE: 20200305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Graham Jonathan P
CENTRAL INDEX KEY: 0001365306
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37702
FILM NUMBER: 20692259
MAIL ADDRESS:
STREET 1: 2099 PENNSYLVANIA AVENUE, NW
STREET 2: 12TH FLOOR
CITY: WASHINGTON
STATE: DC
ZIP: 20006
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 953540776
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER COMPANY:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-03-03
0000318154
AMGEN INC
AMGN
0001365306
Graham Jonathan P
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320-1799
1
EVP, Gen. Counsel & Secy.
Common Stock
2020-03-03
4
A
0
11600
0
A
54571
D
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,001 RSUs which vest in one installment on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; 3,155 RSUs which vest in two installments of 1,041 on 4/27/2020 and 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; and 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 560 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
/s/ Jonathan P. Graham
2020-03-04